Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $4.4 million.

  • Vanda Pharmaceuticals' Other Operating Expenses rose 780.71% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year decrease of 38.17%. This contributed to the annual value of $17.7 million for FY2024, which is 1077.92% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Other Operating Expenses stood at $4.4 million for Q3 2025, which was up 780.71% from $4.2 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' 5-year Other Operating Expenses high stood at $6.8 million for Q3 2021, and its period low was $3.2 million during Q3 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' median Other Operating Expenses value was $5.0 million (recorded in 2025), while the average stood at $5.1 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Other Operating Expenses tumbled by 4932.81% in 2023, and later soared by 2599.44% in 2024.
  • Vanda Pharmaceuticals' Other Operating Expenses (Quarter) stood at $6.2 million in 2021, then grew by 1.64% to $6.3 million in 2022, then tumbled by 33.55% to $4.2 million in 2023, then dropped by 3.04% to $4.1 million in 2024, then increased by 7.97% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.2 million for Q2 2025, and $5.0 million during Q1 2025.